#294 gcig_vignette: style file

pharmaverse · Nov 25, 2024 · e3a73ac · e3a73ac
1 parent 8b53a9c
commit e3a73ac
Show file tree

Hide file tree

Showing 2 changed files with 5 additions and 0 deletions.
diff --git a/inst/WORDLIST b/inst/WORDLIST
@@ -62,4 +62,5 @@ rda
 rds
 responder
 responders
+styler
 timepoint
diff --git a/vignettes/adrs_gcig.Rmd b/vignettes/adrs_gcig.Rmd
@@ -91,6 +91,7 @@ For this vignette we made assumptions that following information is collected on
 2.	The date of CA-125 response is assigned to the date of the first measurement when the CA-125 level is reduced by 50%. The date of CA-125 progression is assigned to the date of the first measurement that meets progression criteria. This is assumed to be collected on the CRF CA-125 response page.
 3.	CA-125 responses are mapped to `CR`, `PR`, `SD`, `PD`, `NE` as shown below.
     ```{r echo=FALSE}
+# styler: off
     list_resp <- tibble::tribble(
       ~"CA-125 response per GCIG",            ~"CA-125 response mapped",
       "Response within Normal Range",         "CR",
@@ -101,12 +102,14 @@ For this vignette we made assumptions that following information is collected on
     )
 
     knitr::kable(list_resp)
+# styler: on
     ```
 
 4.	Combined CA-125 and RECIST 1.1 response per visit where both RECIST 1.1 and CA-125 is evaluated is also collected on the CRF. The investigator should already consider CA-125 confirmed response and each visit RECIST 1.1 response based on GCIG document.
 5. In `SUPPRS` there are records with below `QNAM` and `QLABEL` values:
 
     ```{r echo=FALSE}
+# styler: off
     list_supp <- tibble::tribble(
       ~"QNAM", ~"QLABEL", ~"QVAL", ~"Purpose", ~"Use case",
       "`CA125EFL`", "CA-125 response evaluable", "Y/N", "Indicates population evaluable for CA-125 response (baseline CA-125 >= 2 * ULRR and no mouse antibodies)", "`CA125EFL` variable",
@@ -118,6 +121,7 @@ For this vignette we made assumptions that following information is collected on
 )
 
     knitr::kable(list_supp)
+# styler: on
     ```
 
     If the data are collected by other ways and similar information from `SUPPRS` dataset are not available, they should be derived in advance from `LB` CA-125 measurements records. Information on whether the patient has received mouse antibodies should also be taken into account.